KIDS vs. TNDM, SLNO, CNMD, CDRE, LQDA, INMD, BLFS, RXST, AORT, and MDXG
Should you be buying OrthoPediatrics stock or one of its competitors? The main competitors of OrthoPediatrics include Tandem Diabetes Care (TNDM), Soleno Therapeutics (SLNO), CONMED (CNMD), Cadre (CDRE), Liquidia (LQDA), InMode (INMD), BioLife Solutions (BLFS), RxSight (RXST), Artivion (AORT), and MiMedx Group (MDXG). These companies are all part of the "medical equipment" industry.
OrthoPediatrics vs.
Tandem Diabetes Care (NASDAQ:TNDM) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends.
Tandem Diabetes Care received 276 more outperform votes than OrthoPediatrics when rated by MarketBeat users. However, 64.26% of users gave OrthoPediatrics an outperform vote while only 61.15% of users gave Tandem Diabetes Care an outperform vote.
Tandem Diabetes Care has a net margin of -14.84% compared to OrthoPediatrics' net margin of -15.00%. OrthoPediatrics' return on equity of -5.78% beat Tandem Diabetes Care's return on equity.
Tandem Diabetes Care has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.
Tandem Diabetes Care currently has a consensus target price of $48.44, suggesting a potential upside of 133.10%. OrthoPediatrics has a consensus target price of $39.00, suggesting a potential upside of 68.47%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, equities analysts plainly believe Tandem Diabetes Care is more favorable than OrthoPediatrics.
In the previous week, Tandem Diabetes Care had 56 more articles in the media than OrthoPediatrics. MarketBeat recorded 59 mentions for Tandem Diabetes Care and 3 mentions for OrthoPediatrics. Tandem Diabetes Care's average media sentiment score of 0.66 beat OrthoPediatrics' score of 0.62 indicating that Tandem Diabetes Care is being referred to more favorably in the media.
69.1% of OrthoPediatrics shares are owned by institutional investors. 2.2% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 31.8% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
OrthoPediatrics has lower revenue, but higher earnings than Tandem Diabetes Care. OrthoPediatrics is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.
Summary
Tandem Diabetes Care beats OrthoPediatrics on 10 of the 18 factors compared between the two stocks.
Get OrthoPediatrics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KIDS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OrthoPediatrics Competitors List
Related Companies and Tools
This page (NASDAQ:KIDS) was last updated on 3/4/2025 by MarketBeat.com Staff
Free KIDS Stock Alerts